Evidence map›Paper›PMID 34751162›Full record

ReviewCold Spring Harbor perspectives in medicine2022

Lung Cancer Computational Biology and Resources.

Ling Cai, Guanghua Xiao, David Gerber, John D Minna, Yang Xie

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ling CaiQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Guanghua XiaoQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
David GerberHarrold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas 75390, USA.
John D MinnaHarrold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas 75390, USA.
Yang XieQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
Novel computational approaches to predict drug response and combination effectsR35GM136375 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI XIE, YANG · 2020 to 2024
$2.0M
Integrative Analysis to Identify Therapeutic Targets for Lung CancerR01CA172211 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI XIAO, GUANGHUA · 2013 to 2017
$1.6M
Predicting Adjuvant Chemotherapy Response in Lung CancerR01CA152301 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI XIE, YANG · 2010 to 2014
$1.5M
Integrative Analysis to Identify Regulation Targets of RNA-Binding ProteinsR01GM115473 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI XIE, YANG · 2016 to 2019
$1.3M
NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA152301NCI NIH HHS R01 CA172211NIGMS NIH HHS R01 GM115473NIGMS NIH HHS R35 GM136375
6 · The paper itself

Abstract

Comprehensive clinical, pathological, and molecular data, when appropriately integrated with advanced computational approaches, are transforming the way we characterize and study lung cancer. Clinically, cancer registry and publicly available historical clinical trial data enable retrospective analyses to examine how socioeconomic factors, patient demographics, and cancer characteristics affect treatment and outcome. Pathologically, digital pathology and artificial intelligence are revolutionizing histopathological image analyses, not only with improved efficiency and accuracy, but also by extracting additional information for prognostication and tumor microenvironment characterization. Genetically and molecularly, individual patient tumors and preclinical models of lung cancer are profiled by various high-throughput platforms to characterize the molecular properties and functional liabilities. The resulting multi-omics data sets and their interrogation facilitate both basic research mechanistic studies and translation of the findings into the clinic. In this review, we provide a list of resources and tools potentially valuable for lung cancer basic and translational research. Importantly, we point out pitfalls and caveats when performing computational analyses of these data sets and provide a vision of future computational biology developments that will aid lung cancer translational research.

Indexed as

Computational BiologyLung NeoplasmsArtificial IntelligenceHumansRetrospective StudiesTranslational Research, BiomedicalTumor Microenvironment

Identifiers

PMID34751162
PMCPMC8805643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.